Heparin-affinity Patterns and Composition of Extracellular Superoxide Dismutase in Human Plasma and Tissues
Overview
Authors
Affiliations
The tetrameric extracellular superoxide dismutase (EC-SOD) in human tissues and plasma has previously been found to be heterogenous with regard to heparin affinity and could be divided into at least three classes: A, lacking heparin affinity; B, with weak affinity; and C, with strong affinity. Using rigorous extraction conditions and an extensive set of anti-proteolytic agents, tissue EC-SOD is now shown to be almost exclusively of native homotetrameric C-class. Plasma EC-SOD on the other hand is shown to be mainly composed of a complex mixture of heterotetramers with modifications probably residing in the C-terminal heparin-binding domain. Proteolytic truncations appear to be a major cause of this heterogeneity. The findings suggest that, since 99% of the EC-SOD in the human body exists in the extravascular space of tissue, EC-SOD is primarily synthesized in tissues and secreted as homotetrameric native EC-SOD C. This tissue EC-SOD C should exist almost completely sequestered by heparin sulphate proteoglycans. C-terminal modifications subsequently occurring in the EC-SOD C would weaken the binding to heparan sulphate proteoglycan, facilitate entrance to the vasculature through capillaries and lymph flow, and finally result in the heterogeneous plasma EC-SOD pattern. With the new extraction and analysis procedure, the tissue content of EC-SOD is found to be higher than previously reported. It is found, for example, when compared with Mn-SOD, to be higher in umbilical cord and uterus, about equal in placenta and testis and as high as that of CuZn-SOD in umbilical cord. The findings suggest that the protection level against superoxide radicals provided by EC-SOD in the tissue interstitial space, given the small distribution volume, is not much less prominent than that bestowed on the intracellular space by CuZn-SOD and Mn-SOD.
Effect of Gossypol on Gene Expression in Swine Granulosa Cells.
Hong M, Kim H, Choi S, Sharma N, Lee S Toxins (Basel). 2024; 16(10).
PMID: 39453212 PMC: 11511463. DOI: 10.3390/toxins16100436.
Impact of EcSOD Perturbations in Cancer Progression.
OLeary B, Carroll R, Steers G, Hrabe J, Domann F, Cullen J Antioxidants (Basel). 2021; 10(8).
PMID: 34439467 PMC: 8388922. DOI: 10.3390/antiox10081219.
Extracellular superoxide dismutase and its role in cancer.
Griess B, Tom E, Domann F, Teoh-Fitzgerald M Free Radic Biol Med. 2017; 112:464-479.
PMID: 28842347 PMC: 5685559. DOI: 10.1016/j.freeradbiomed.2017.08.013.
Milenkovic J, Vojinovic J, Debeljak M, Toplak N, Lazarevic D, Avcin T Pediatr Rheumatol Online J. 2016; 14(1):39.
PMID: 27364639 PMC: 4929733. DOI: 10.1186/s12969-016-0097-1.
Kobylecki C, Afzal S, Nordestgaard B EBioMedicine. 2016; 2(12):2010-5.
PMID: 26844281 PMC: 4703764. DOI: 10.1016/j.ebiom.2015.11.026.